BLUE BELL, Pa., Oct. 15, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its majority-owned subsidiary, VGX Animal Health, has received approval to market LifeTide® SW 5.0, the world's first approved growth hormone releasing hormone (GHRH) therapy for food animals, in New Zealand. LifeTide is a once-in-a-lifetime treatment for female pigs (sows) that has demonstrated significant decreases in perinatal mortality of piglets from treated sows compared to untreated sows. The treatment, which increases the number of weaned piglets and results in greater overall meat production, was previously approved in Australia.
"We've seen that when perinatal mortality is significantly reduced, pork producers can quickly realize production and profit benefits never before imagined," said Dr. Douglas Kern, DVM, and Vice President of Business Development for VGX Animal Health.Dr. J. Joseph Kim, Chairman of VGX Animal Health and CEO of Inovio Pharmaceuticals, said, "This approval is another milestone for DNA plasmid therapy, where Inovio leads the world. Our plasmid-based technology platform provided this breakthrough in animal health and has demonstrated in humans its safety and immune responses in therapeutic and preventive vaccines for cancer, HIV, influenza and other infectious diseases in proof-of-principle clinical studies. "We are investigating GHRH therapy in other veterinary as well as human disease areas since it has shown promise in treating a broad array of diseases such as cancer, HIV-associated lipodystrophy, diabetes, Alzheimer's and conditions that affect the kidney and heart." The New Zealand approval is particularly significant in that genetically modified (GMO) products are not allowed in the country. Given the New Zealand stance on GMO technologies, VGXAH's ability to gain market approval for their non-GMO DNA based therapy is a testament to the safety and sustainability of this technology platform. The ability to enhance the genetic potential of the pig without permanently altering its genetic makeup is an important step forward in the effort to feed the United Nation's estimated 1 billion food-insecure people around the world. VGX Animal Health's accomplishment is an important step in developing technologies to enhance the world's ability to feed a population that will require a doubling of the amount of food we produce within the next four decades. For areas of the world concerned with preserving genetic diversity, this technology offers great promise. Growth hormone releasing hormone or GHRH is a naturally occurring molecule that stimulates the body's pituitary gland to release growth hormone that it produces every day.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts